Printer Friendly

NORTRAN RESOURCES LTD. SIGNS INTERIM RESEARCH AGREEMENT

 NORTRAN RESOURCES LTD. SIGNS INTERIM RESEARCH AGREEMENT
 VANCOUVER, British Columbia, March 23 /PRNewswire/ -- The board of


directors is pleased to report that Nortran Resources Ltd. (Vancouver: NRT), through its 50 percent-owned pharmaceutical research and development company, Rhythm Search Developments Ltd., has signed an interim research agreement with a group at a major Canadian university to gain an interest in a group of new drugs for blocking pain. This endeavour, together with the aerotherapeutic (ATM) technology, is complimentary to Rhythm Search's research mission of developing ion channel drugs and methods for their administration.
 These pain-blocking drugs, called "Selective Nociceptor Blockers," have the potential for blocking pain sensation without having side effects due to action in the brain. This contrasts with currently used local anaesthetic drugs, whose use is limited by such side effects. The annual market for these new drugs is estimated at $100 million. The discoverers, in conjunction with the university, expect to be filing their first patent application on Selective Nociceptor Blockers by June.
 The interim research agreement provides Rhythm Search with a first option on an exclusive license, for consideration, on all Selective Nociceptor Blockers invented by the research group up to June 30, 1992. Pending the outcome of the current research, Rhythm Search will begin negotiation on the terms and conditions of a long term, exclusive arrangement. More details of the drug discovery and the researchers involved will be released, upon a successful outcome of current negotiations.
 Rhythm Search management also reports progress on its evaluation and feasibility studies on aerotherapeutic (ATM) technology. The company recently acquired a right of first refusal on novel ATM technology from Dr. Gregory Polyakov, a surgeon of 16 years and the proponent and inventor on some of the technology. Rhythm Search has engaged the services of engineers at the British Columbia Research Corp. to provide an evaluation of both new and old ATM technology. B.C. Research will also assist in preparing the data required for application for patent protection of Polyakov's new ATM technology. This contract is being supported in part by a grant from the province of British Columbia through their Technology Assistance program.
 Before commencing due diligence investigations on these projects, the management of Rhythm Search demonstrated to Nortran's board that the projects conform to the requirements of Rhythm Search's strategic plan for corporate stability, cash flow, and capital appreciation. To date, Nortran has contributed $25,000 to Rhythm Search for their support of the ATM and the antinociceptive drug projects.
 Rhythm Search is a pharmaceutical research and development company. Nortran, a venture capital company, owns 50 percent of Rhythm Search with an option to acquire the remaining 50 percent.
 -0- 3/23/92
 /CONTACT: David Robinson of Nortran Resources Ltd., 604-685-7933, or U.S. Toll Free 800-665-7037/
 (NRT.)


CO: Nortran Resources Ltd. ST: British Columbia IN: MTC SU: PDT

AL -- LA014 -- 0615 03/23/92 13:31 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 23, 1992
Words:481
Previous Article:GROWING EMPLOYMENT IN FAYETTEVILLE, WILMINGTON AREAS SPURS HOUSING DEMAND
Next Article:EMPI RESPONDS TO STOCK ACTIVITY
Topics:


Related Articles
NORTRAN RESOURCES LTD. ANNOUNCES EQUITY ACQUISITION
NORTRAN RESOURCES LTD. ANNOUNCES AGREEMENT WITH RHYTHM SEARCH DEVELOPMENTS LTD.
NORTRAN RESOURCES LTD. ANNOUNCES ACQUISITION OF RHYTHM SEARCH DEVELOPMENTS
NORTRAN RESOURCES LTD. ANNOUNCES APPOINTMENT OF GORDON POLITESKI AS PRESIDENT AND DIRECTOR
NORTRAN PHARMACEUTICALS ANNOUNCES KEY APPOINTMENT TO BOARD OF DIRECTORS
PHARMACEUTICAL RESOURCES IN DISCUSSIONS WITH DR. REDDY'S GROUP REGARDING SUPPLY AGREEMENT
Cortech Amends Agreement With Ono Pharmaceutical Company, Ltd.
Therapeutic Antibodies Announces Second Quarter Results

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters